Ikarian Capital’s Immunovant IMVT Stock Holding History

Ikarian Capital’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-300,000	Closed	-$7.43M	–	192
2024 Q4	$7.43M	Sell	300,000 -200,000	-40%	-$5.67M	1.01%	25
2024 Q3	$14.3M	Buy	500,000 +499,000	+49,900%	+$14.7M	1.99%	9
2024 Q2	$2.64M	Buy	+1,000	New	+$28.4K	0.46%	50
2024 Q1	–	Sell	-300,700	Closed	-$12.7M	–	160
2023 Q4	$12.7M	Buy	300,700 +293,470	+4,059%	+$10.8M	1.19%	27
2023 Q3	$27.8M	Sell	7,230 -318,970	-98%	-$7.21M	3.34%	6
2023 Q2	$6.19M	Buy	326,200 +165,900	+103%	+$3.09M	0.99%	32
2023 Q1	$2.49M	Buy	160,300 +134,100	+512%	+$2.33M	0.56%	52
2022 Q4	$465K	Buy	+26,200	New	+$330K	0.11%	60
2021 Q3	–	Sell	-400,000	Closed	-$4.23M	–	238
2021 Q2	$4.23M	Buy	400,000 +38,300	+11%	+$535K	0.34%	76
2021 Q1	$5.8M	Buy	+361,700	New	+$9.54M	0.2%	109

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Ikarian Capital's IMVT Position: Q1 2025 in Review

Ikarian Capital sold out of Immunovant (IMVT) in Q1 2025, closing a stake of 600 shares — an estimated $12.6K sold.

Ikarian Capital first reported a position in IMVT in Q4 2019 and held it in 15 quarters. The position peaked at $17.2M in Q4 2022. 193 funds tracked by Wall St. Rank hold IMVT as of Q1 2025.

Ikarian Capital reported no remaining Immunovant position as of Q1 2025 after selling out during the quarter.
Ikarian Capital sold 600 Immunovant shares in Q1 2025, an estimated $12.6K.
Ikarian Capital first reported a position in Immunovant in Q4 2019 and held it in 15 quarters.
Ikarian Capital's Immunovant position peaked at $17.2M in Q4 2022.
193 funds tracked by Wall St. Rank held Immunovant as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.